Eye radiation therapy for persistent wet macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new radiation treatment for people with wet age-related macular degeneration (AMD) that hasn't fully responded to standard eye injections. The treatment aims to reduce the need for ongoing injections and help maintain vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wet age-related macular degeneration (AMD) that is still active despite treatment.
- You have had at least 3 anti-VEGF injections (like Eylea or Lucentis) without missing any doses.
- You have not had radiation therapy to your head or neck in the past.
- You do not have diabetes (type 1 or 2).
- Your vision in the study eye is better than 20/400 (roughly counting fingers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether aflibercept injections can help when “wet” age-related macular degeneration is recurring or not fully going away. It focuses on adults who have already had ranibizumab and still have measurable vision in the study eye.
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.